Search Results

You are looking at 311 - 320 of 526 items for :

  • "Adjuvant therapy" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Survivorship in Non–Small Cell Lung Cancer: Challenges Faced and Steps Forward

Namrata Vijayvergia, Prashant C. Shah, and Crystal S. Denlinger

neuropathy and hearing loss persisted throughout the study follow-up period, up to 30 months posttreatment. 21 These results suggest that adjuvant therapy improves survival at a cost of short-term decline in global QOL, which improves to a significant degree

Full access

Role of Immunotherapy in Triple-Negative Breast Cancer

Tanya E. Keenan and Sara M. Tolaney

compared with chemotherapy alone in TNBC recurring within 1 year of adjuvant therapy. Table 2. Ongoing Anti–PD-1/L1 Combination and Novel Immunotherapy Trials in TNBC Early-Stage Chemotherapy Combination Regimens The combination of ICIs with chemotherapy in

Full access

NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022

Featured Updates to the NCCN Guidelines

Jimmy J. Caudell, Maura L. Gillison, Ellie Maghami, Sharon Spencer, David G. Pfister, Douglas Adkins, Andrew C. Birkeland, David M. Brizel, Paul M. Busse, Anthony J. Cmelak, A. Dimitrios Colevas, David W. Eisele, Thomas Galloway, Jessica L. Geiger, Robert I. Haddad, Wesley L. Hicks Jr, Ying J. Hitchcock, Antonio Jimeno, Debra Leizman, Loren K. Mell, Bharat B. Mittal, Harlan A. Pinto, James W. Rocco, Cristina P. Rodriguez, Panayiotis S. Savvides, David Schwartz, Jatin P. Shah, David Sher, Maie St. John, Randal S. Weber, Gregory Weinstein, Frank Worden, Justine Yang Bruce, Sue S. Yom, Weining Zhen, Jennifer L. Burns, and Susan D. Darlow

adjuvant therapy better. Omitting systemic therapy and administering RT alone is a category 2B option for patients with p16-positive cT0–2, cN0–1 disease (single node ≤3 cm) who have extranodal extension following surgery. For patients with positive or

Full access

Colon Cancer, Version 3.2014

Al B. Benson III, Alan P. Venook, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Ahmed Kamel, Lucille A. Leong, Edward Lin, Wells Messersmith, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Kristina M. Gregory, and Deborah A. Freedman-Cass

-containing chemotherapeutic regimens are administered. 22 To limit the development of hepatotoxicity, it is therefore recommended that surgery be performed as soon as possible after the patient becomes resectable. Neoadjuvant and Adjuvant Therapy for Resectable

Full access

Preventing Overdiagnosis and Overtreatment: Just the Next Step in the Evolution of Breast Cancer Care

Rita A. Mukhtar, Jasmine M. Wong, and Laura J. Esserman

opportunities to further refine the current state of the art. Overdiagnosis occurs when tumors that would otherwise not become symptomatic are identified. Overtreatment occurs when such a tumor is treated, often with surgery and adjuvant therapy in the case of

Full access

Prostate Cancer, Version 1.2016

James L. Mohler, Andrew J. Armstrong, Robert R. Bahnson, Anthony Victor D'Amico, Brian J. Davis, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric M. Horwitz, Michael Hurwitz, Christopher J. Kane, Mark H. Kawachi, Michael Kuettel, Richard J. Lee, Joshua J. Meeks, David F. Penson, Elizabeth R. Plimack, Julio M. Pow-Sang, David Raben, Sylvia Richey, Mack Roach III, Stan Rosenfeld, Edward Schaeffer, Ted A. Skolarus, Eric J. Small, Guru Sonpavde, Sandy Srinivas, Seth A. Strope, Jonathan Tward, Dorothy A. Shead, and Deborah A. Freedman-Cass

diagnosed prostate cancer who are considering active surveillance, and in treated men who are considering adjuvant therapy or therapy for recurrences. Uncertainty about the risk of disease progression can be reduced if such molecular assays can accurately

Full access

Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma

Tobin Strom, Javier F. Torres-Roca, Akash Parekh, Arash O. Naghavi, Jimmy J. Caudell, Daniel E. Oliver, Jane L. Messina, Nikhil I. Khushalani, Jonathan S. Zager, Amod Sarnaik, James J. Mulé, Andy M. Trotti, Steven A. Eschrich, Vernon K. Sondak, and Louis B. Harrison

were defined as having an RSI GES <0.3745 and RSI-high tumors as having an RSI GES ≥0.3745. Systemic Therapy Adjuvant therapy was delivered within 4 to 6 months of surgery and before recurrence at any site to 156 patients (38.0%), and included

Full access

Multimodality Approaches for the Curative Treatment of Esophageal Cancer

Raymond Jang, Gail Darling, and Rebecca K.S. Wong

adjuvant therapy. The patients were Japanese with SCC histology, and adjuvant therapy consisted of 2 cycles of cisplatin and fluorouracil. Recommendations: The Ontario guidelines panel recommended the use of preoperative platinumbased chemotherapy plus

Full access

Quality Measurement in Cancer Care: A Review and Endorsement of High-Impact Measures and Concepts

Thomas A. D’Amico, Lindsey A.M. Bandini, Alan Balch, Al B. Benson III, Stephen B. Edge, C. Lyn Fitzgerald, Robert J. Green, Wui-Jin Koh, Michael Kolodziej, Shaji Kumar, Neal J. Meropol, James L. Mohler, David Pfister, Ronald S. Walters, and Robert W. Carlson

determine whether cancer has recurred in some cancer types. Unfortunately, no tumor marker in breast cancer is accurate or leads to outcome improvements for women who have completed therapy with curative intent (eg adjuvant therapy) and are undergoing

Full access

Prevalence of Insomnia in an Oncology Patient Population: An Irish Tertiary Referral Center Experience

Emily C. Harrold, Ahmad F. Idris, Niamh M. Keegan, Lynda Corrigan, Min Yuen Teo, Martin O’Donnell, Sean Tee Lim, Eimear Duff, Dearbhaile M. O’Donnell, M. John Kennedy, Sue Sukor, Cliona Grant, David G. Gallagher, Sonya Collier, Tara Kingston, Ann Marie O’Dwyer, and Sinead Cuffe

have been identified up to 5 years after initiation of adjuvant therapy for cancer, and insomnia continues to remain a significant issue among long-term survivors (>5 years), 28 , 29 illustrating the chronicity of this sleep disturbance. Sleep